Royalty Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	477.01	1,711	1,541	1,009	246.2	1,924
Short-Term Investments	756.74	717.04	1,262	1,640	547.02	461.82
Cash & Cash Equivalents	1,234	2,428	2,803	2,649	793.21	2,386
Cash Growth	-49.18%	-13.39%	5.82%	233.97%	-66.76%	-
Receivables	36.65	36.6	68.31	39.17	38.77	198.63
Other Current Assets	3.8	90.52	6.63	8.6	0.09	23.9
Total Current Assets	1,274	2,555	2,878	2,697	832.07	2,609
Long-Term Investments	15,101	14,229	14,628	13,285	11,478	8,667
Goodwill and Intangibles	0	0	5.67	28.67	51.72	75.65
Other Long-Term Assets	6.52	29.63	4.15	10	87.95	19.11
Total Long-Term Assets	15,108	14,259	14,638	13,323	11,618	8,762
Total Assets	16,382	16,813	17,516	16,020	12,450	11,370
Accounts Payable	15.17	7.91	5.62	10.78	11.18	298.74
Current Debt	0	997.51	0	0	281.98	281.44
Other Current Liabilities	146.21	161.37	165.63	297.11	40.26	0
Total Current Liabilities	161.38	1,167	171.25	307.89	333.42	580.17
Long-Term Debt	6,135	6,119	7,096	5,817	5,956	6,238
Other Long-Term Liabilities	0.9	2.5	0	0	18.9	0
Total Long-Term Liabilities	6,136	6,121	7,096	5,817	5,975	6,238
Total Liabilities	6,298	7,288	7,267	6,124	6,308	6,818
Total Debt	6,135	7,116	7,096	5,817	6,238	6,519
Debt Growth	-13.79%	0.29%	22.00%	-6.76%	-4.31%	-
Retained Earnings	2,518	1,965	2,255	1,921	2,825	1,216
Comprehensive Income	0	0	16.49	34.4	2.09	-10.26
Shareholders' Equity	10,084	9,525	10,249	9,896	6,106	4,488
Net Cash / Debt	-4,901.54	-4,688.53	-4,292.8	-3,167.45	-5,444.91	-4,133.3
Net Cash Per Share	-8.13	-10.71	-10.35	-8.44	-	-
Working Capital	1,113	1,388	2,707	2,389	498.66	2,028
Book Value Per Share	22.53	21.75	24.71	26.36	10.26	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).